News, Links and Commentary
Monday, June 13, 2005
Non-Viral Gene Therapy Technology Showing Favourable Results
Non-viral forms of gene therapy, such as Copernicus Therapeutics' non-viral nucleic acid nanoparticle technology, may be part of future treatments for neurological disorders such as retinitis pigmentosa and macular degeneration. Researchers from the University of Kentucky and the University of Oklahoma announced trial results at the American Society of Gene Therapy Meeting in St Louis, Missouri, USA earlier this month.
"We are most enthusiastic about these findings," said Dr. Mark J. Cooper, Sr. Vice President of Science and Medical Affairs at Copernicus. "Gene transfer in the brain of animals was highly efficient and non-toxic, suggesting multiple treatment options for serious neurological disorders such as Parkinson's and Alzheimer's diseases. In the eye, a remarkable 99% gene transfer efficiency in the retina was observed. Treatment of important causes of blindness, including retinitis pigmentosa, macular degeneration, diabetic retinopathy, and various viral infections may be possible using our nanoparticle technology."
'Copernicus Announces Efficient DNA Drug Delivery for Brain & Eye Diseases' (Copernicus Therapeutics, Inc. media release at PharmaLive.com, 7 June 2005).
Comments:
Post a Comment
